
Edgewise (EWTX) | Stock Overview & Key Data
Edgewise Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $40.49 on March 29, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Edgewise EWTX | 1.47B Small-cap | 4.95% | 9.19% | 0.21% | -45.99% | -45.91% | -24.37% | 49.03% | -51.27% |
Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
Cg Oncology CGON | 1.99B Small-cap | 0.08% | -3.42% | -0.92% | -6.71% | -10.32% | -29.82% | -25.83% | -25.83% |
Adaptive ADPT | 1.99B Small-cap | -2.24% | 22.50% | 38.94% | 52.72% | 104.04% | 159.88% | 20.52% | -69.05% |
Vericel VCEL | 1.80B Small-cap | -0.92% | -0.06% | -13.71% | -31.85% | -35.69% | -28.10% | 30.92% | 116.49% |
Ownership & Short Interest
Edgewise Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Edgewise would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is EWTX's 52-week high and low?
- In the last 52 weeks, Edgewise reached a high of $38.12 (on November 11, 2024) and a low of $10.60 (on April 7, 2025).
- What is the market cap and P/E ratio for EWTX?
- Curious about Edgewise's size and valuation? Its market capitalization stands at 1.47B. When it comes to valuation, the P/E ratio (trailing twelve months) is -9.52, and the forward P/E (looking ahead) is -7.57.
- Does EWTX pay dividends? If so, what's the yield?
- As for dividends, Edgewise isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Edgewise's main competitors or similar companies to consider before investing?
When looking at Edgewise, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% Cg Oncology
CGON1.99B Healthcare Biotechnology -29.82% -25.83% Adaptive
ADPT1.99B Healthcare Biotechnology 159.88% 20.52% Vericel
VCEL1.80B Healthcare Biotechnology -28.10% 30.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Edgewise Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Edgewise's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -27.41%, the Debt to Equity ratio from the most recent quarter is 0.74, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for EWTX?
- Looking at Edgewise's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of EWTX stock is held by insiders and institutions?
- Wondering who owns Edgewise stock? Company insiders (like executives and directors) hold about 0.44% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 116.64%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.